Hubbry Logo
Sensorineural hearing lossSensorineural hearing lossMain
Open search
Sensorineural hearing loss
Community hub
Sensorineural hearing loss
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Sensorineural hearing loss
Sensorineural hearing loss
from Wikipedia
Sensorineural hearing loss
Cross-section of the cochlea.
SpecialtyOtorhinolaryngology

Sensorineural hearing loss (SNHL) is a type of hearing loss in which the root cause lies in the inner ear, sensory organ (cochlea and associated structures), or the vestibulocochlear nerve (cranial nerve VIII). SNHL accounts for about 90% of reported hearing loss.[citation needed] SNHL is usually permanent and can be mild, moderate, severe, profound, or total. However, if the loss happened suddenly, and very recently, Prednisone and other treatments may reverse the loss (See SSHL below). Various other descriptors can be used depending on the shape of the audiogram, such as high frequency, low frequency, U-shaped, notched, peaked, or flat.

Sensory hearing loss often occurs as a consequence of damaged or deficient cochlear hair cells.[disputeddiscuss] Hair cells may be abnormal at birth or damaged during the lifetime of an individual. There are both external causes of damage, including infection, and ototoxic drugs, as well as intrinsic causes, including genetic mutations. A common cause or exacerbating factor in SNHL is prolonged exposure to environmental noise, or noise-induced hearing loss. Exposure to a single very loud noise, such as a gunshot or bomb blast, can cause noise-induced hearing loss. Using headphones at high volume over time, or being in loud environments regularly, such as a loud workplace, sporting events, concerts, and using noisy machines, can also be a risk for noise-induced hearing loss.

Neural, or "retrocochlear", hearing loss occurs because of damage to the cochlear nerve (CVIII). This damage may affect the initiation of the nerve impulse in the cochlear nerve or the transmission of the nerve impulse along the nerve into the brainstem.

Most cases of SNHL present with a gradual deterioration of hearing thresholds occurring over years to decades. In some, the loss may eventually affect large portions of the frequency range. It may be accompanied by other symptoms such as ringing in the ears (tinnitus) and dizziness or lightheadedness (vertigo). The most common kind of sensorineural hearing loss is age-related (presbycusis), followed by noise-induced hearing loss (NIHL).

Frequent symptoms of SNHL are loss of acuity in distinguishing foreground voices against noisy backgrounds, difficulty understanding on the telephone, some kinds of sounds seeming excessively loud or shrill, difficulty understanding some parts of speech (fricatives and sibilants), loss of directionality of sound (especially with high frequency sounds), perception that people mumble when speaking, and difficulty understanding speech. Similar symptoms are also associated with other kinds of hearing loss; audiometry or other diagnostic tests are necessary to distinguish sensorineural hearing loss.

Identification of sensorineural hearing loss is usually made by performing a pure tone audiometry (an audiogram) in which bone conduction thresholds are measured. Tympanometry and speech audiometry may be helpful. Testing is performed by an audiologist.

There is no proven or recommended treatment or cure for SNHL; management of hearing loss includes hearing strategies and hearing aids. In cases of profound or total deafness, a cochlear implant is a specialised device that may restore a functional level of hearing. SNHL is at least partially preventable by avoiding environmental noise, ototoxic chemicals and drugs, and head trauma, and treating or inoculating against certain triggering diseases and conditions like meningitis.

Signs and symptoms

[edit]

Since the inner ear is not directly accessible to instruments, identification is by patient report of the symptoms and audiometric testing. Of those who present to their doctor with sensorineural hearing loss, 90% report having diminished hearing, 57% report having a plugged feeling in the ear, and 49% report having ringing in the ear (tinnitus). About half report vestibular (vertigo) problems.[citation needed]

For a detailed exposition of symptoms useful for screening, a self-assessment questionnaire was developed by the American Academy of Otolaryngology, called the Hearing Handicap Inventory for Adults (HHIA). It is a 25-question survey of subjective symptoms.[1]

Causes

[edit]

Sensorineural hearing loss may be genetic or acquired (i.e., as a consequence of disease, noise, trauma, etc.). People may have a hearing loss from birth (congenital) or the hearing loss may come on later. Many cases are related to old age (age-related).[citation needed]

Genetic

[edit]

Hearing loss can be inherited. More than 40 genes have been implicated in the cause of deafness.[2] There are 300 syndromes with related hearing loss, and each syndrome may have causative genes.[citation needed]

Recessive, dominant, X-linked, or mitochondrial genetic mutations can affect the structure or metabolism of the inner ear. Some may be single point mutations, whereas others are due to chromosomal abnormalities. Some genetic causes give rise to a late-onset hearing loss. Mitochondrial mutations can cause SNHL, i.e., m.1555A>G, which makes the individual sensitive to the ototoxic effects of aminoglycoside antibiotics.[citation needed]

  • The most common cause of recessive genetic congenital hearing impairment in developed countries is DFNB1, also known as Connexin 26 deafness or GJB2-related deafness.
  • The most common syndromic forms of hearing impairment include (dominant) Stickler syndrome and Waardenburg syndrome, and (recessive) Pendred syndrome and Usher syndrome.
  • Mitochondrial mutations causing deafness are rare: MT-TL1 mutations cause MIDD (Maternally inherited deafness and diabetes) and other conditions, which may include deafness as part of the picture.
  • TMPRSS3 gene was identified by its association with both congenital and childhood-onset autosomal recessive deafness. This gene is expressed in fetal cochleae and many other tissues, and is thought to be involved in the development and maintenance of the inner ear or the contents of the perilymph and endolymph. It was also identified as a tumor-associated gene that is overexpressed in ovarian tumors.
  • Charcot–Marie–Tooth disease[3] an inherited neurological disorder with delayed onset that can affect the ears as well as other organs. The hearing loss in this condition is often ANSD (auditory neuropathy spectrum disorder), a neural cause of hearing loss.
  • Muckle–Wells syndrome, a rare inherited autoinflammatory disorder, can lead to hearing loss.
  • Autoimmune disease: Although probably rare, it is possible for autoimmune processes to target the cochlea specifically, without symptoms affecting other organs. Granulomatosis with polyangiitis, an autoimmune condition, may precipitate hearing loss.

Congenital

[edit]

Presbycusis

[edit]

Progressive age-related loss of hearing acuity or sensitivity can start as early as age 18, primarily affecting the high frequencies, and men more than women.[6] Such losses may not become apparent until much later in life. Presbycusis is by far the dominant cause of sensorineural hearing loss in industrialized societies. A study conducted in Sudan, with a population free from loud noise exposures, found significantly fewer cases of hearing loss when compared with age-matched cases from an industrialized country.[7] Similar findings were reported by a study conducted of a population from Easter island, which reported worse hearing among those that spent time in industrialized countries when compared with those that never left the island.[8] Researchers have argued that factors other than differences in noise exposure, such as genetic make up, might also have contributed to the findings.[9] Hearing loss that worsens with age but is caused by factors other than normal aging, such as noise-induced hearing loss, is not presbycusis, although differentiating the individual effects of multiple causes of hearing loss can be difficult. One in three people has significant hearing loss by age 65; by age 75, one in two. Age-related hearing loss is neither preventable nor reversible.[citation needed]

Noise

[edit]

Most people living in modern society have some degree of progressive sensorineural (i.e., permanent) noise-induced hearing loss (NIHL) resulting from overloading and damaging the sensory or neural apparatus of hearing in the inner ear.[citation needed] NIHL is typically a drop-out or notch centered at 4000 Hz. Both intensity (SPL) and duration of exposure, and repetitive exposure to unsafe levels of noise contribute to cochlear damage that results in hearing loss. The louder the noise is, the shorter the safe amount of exposure is. NIHL can be either permanent or temporary, called a threshold shift. Unsafe levels of noise can be as little as 70 dB (about twice as loud as normal conversation) if there is prolonged (24-hour) or continuous exposure. 125 dB (a loud rock concert is ~120 dB) is the pain level; sounds above this level cause instant and permanent ear damage.[citation needed]

Noise and ageing are the primary causes of presbycusis, or age-related hearing loss, the most common kind of hearing loss in industrial society.[10][citation needed] The dangers of environmental and occupational noise exposure are widely recognized. Numerous national and international organizations have established standards for safe levels of exposure to noise in industry, the environment, military, transportation, agriculture, mining and other areas.[Note 1] Sound intensity or sound pressure level (SPL) is measured in decibels (dB). For reference:

db Level Example
45 dB Ambient noise level around the home
60 dB Quiet office
60–65 dB Normal conversation
70 dB City street noise at 25 ft (7.6 m) or average TV audio
80 dB Noisy office
95–104 dB Nightclub dance floor
120 dB Close-by thunder or a loud rock concert
150–160 dB Gunshot from a handheld gun

An increase of 6 dB represents a doubling of the SPL, or energy of the sound wave, and therefore its propensity to cause ear damage. Because human ears hear logarithmically, not linearly, it takes an increase of 10 dB to produce a sound that is perceived to be twice as loud. Ear damage due to noise is proportional to sound intensity, not perceived loudness, so it is misleading to rely on subjective perception of loudness as an indication of the risk to hearing, i.e. it can significantly underestimate the danger.[citation needed]

While the standards differ moderately in levels of intensity and duration of exposure considered safe, some guidelines can be derived.[Note 2]

The safe amount of exposure is reduced by a factor of 2 for every exchange rate (3 dB for NIOSH standard or 5 dB for OSHA standard) increase in SPL. For example, the safe daily exposure amount at 85 dB (90 dB for OSHA) is 8 hours, while the safe exposure at 94 dB(A) (nightclub level) is only 1 hour. Noise trauma can also cause a reversible hearing loss, called a temporary threshold shift. This typically occurs in individuals who are exposed to gunfire or firecrackers and hear ringing in their ears after the event (tinnitus).[citation needed]

  • Ambient environmental noise: Populations living near airports, railyards and train stations, freeways and industrial areas are exposed to levels of noise typically in the 65 to 75 dBA range. If lifestyles include significant outdoor or open window conditions, these exposures over time can degrade hearing. U.S. Dept. of Housing and Urban Development sets standards for noise impact in residential and commercial construction zones. HUD's noise standards may be found in 24 CFR Part 51, Subpart B. Environmental noise above 65 dB defines a noise-impacted area.
  • Personal audio electronics: Personal audio equipment such as iPods (iPods often reach 115 decibels or higher), can produce powerful enough sound to cause significant NIHL.[11]
  • Acoustic trauma: Exposure to a single event of extremely loud noise (such as explosions) can also cause temporary or permanent hearing loss. A typical source of acoustic trauma is a too-loud music concert.
  • Workplace noise: The OSHA standards 1910.95 General Industry Occupational Noise Exposure and 1926.52 Construction Industry Occupational Noise Exposure identify the level of 90 dB(A) for 8-hour exposure as the level necessary to protect workers from hearing loss.

Disease or disorder

[edit]
  • Inflammatory
    • Suppurative labyrinthitis or otitis interna (inflammation of the inner ear)
  • Diabetes mellitus A recent study[as of?] found that hearing loss is twice as common in people with diabetes as it is in those who do not have the disease.[citation needed] Also, of the 86 million adults in the U.S. who have prediabetes, the rate of hearing loss is 30 percent higher than in those with normal blood glucose.[citation needed] It has not been established how diabetes is related to hearing loss. It is possible that the high blood glucose levels associated with diabetes cause damage to the small blood vessels in the inner ear, similar to the way in which diabetes can damage the eyes and the kidneys. Similar studies have shown a possible link between hearing loss and neuropathy (nerve damage).
  • Tumor
  • Ménière's disease – causes sensorineural hearing loss in the low frequency range (125 Hz to 1000 Hz). Ménière's disease is characterized by sudden attacks of vertigo, lasting minutes to hours, preceded by tinnitus, aural fullness, and fluctuating hearing loss. It is relatively rare and commonly overdiagnosed.
  • Bacterial meningitis, e.g., pneumococcal, meningococcal, Haemophilus influenzae, may damage the cochlea – hearing loss is one of the most common after-effects of bacterial meningitis. It has been estimated that 30% of bacterial meningitis cases result in mild to profound hearing loss. Children are most at risk: seventy percent of all bacterial meningitis occurs in young children under the age of five.
  • Viral
    • AIDS and ARC patients frequently experience auditory system anomalies.
    • Mumps(epidemic parotitis) may result in profound sensorineural hearing loss (90 dB or more), unilaterally (one ear) or bilaterally (both ears).
    • Measles may result in auditory nerve damage, but more commonly gives a mixed (sensorineural plus conductive) hearing loss, and can be bilateral.
    • Ramsay Hunt syndrome type II (herpes zoster oticus)
  • Bacterial
    • Syphilis is commonly transmitted from pregnant women to their fetuses, and about a third of the infected children will eventually become deaf.

Ototoxic and neurotoxic drugs and chemicals

[edit]

Some over-the-counter as well as prescription drugs and certain industrial chemicals are ototoxic. Exposure to these can result in temporary or permanent hearing loss.

Some medications cause irreversible damage to the ear and are limited in their use for this reason. The most important group is the aminoglycosides (main member gentamicin). A rare mitochondrial mutation, m.1555A>G, can increase an individual's susceptibility to the ototoxic effect of aminoglycosides. Long-term heavy use of hydrocodone (Vicodin) is known to cause rapidly progressing sensorineural hearing loss, usually without vestibular symptoms. Methotrexate, a chemotherapy agent, is also known to cause hearing loss. In most cases, hearing loss does not recover when the drug is stopped. Paradoxically, methotrexate is also used in the treatment of autoimmune-induced inflammatory hearing loss.[citation needed]

Various other medications may reversibly degrade hearing. This includes loop diuretics, sildenafil (Viagra), high or sustained dosing of NSAIDs (aspirin, ibuprofen, naproxen, and various prescription drugs: celecoxib, etc.), quinine, and macrolide antibiotics (erythromycin, etc.). Cytotoxic agents such as carboplatinum, used to treat malignancies, can give rise to a dose-dependent SNHL, as can drugs such as desferrioxamine, used for haematological disorders such as thalassaemia; patients prescribed these drugs need to have their hearing monitored.[citation needed]

Prolonged or repeated environmental or work-related exposure to ototoxic chemicals can also result in sensorineural hearing loss. Some of these chemicals are:

Head trauma

[edit]

There can be damage either to the ear itself or to the central auditory pathways that process the information conveyed by the ears. People who sustain a head injury are susceptible to hearing loss or tinnitus, either temporary or permanent. Contact sports like football (U.S. NFL), hockey, and cricket have a notable incidence of head injuries (concussions). In one survey of retired NFL players, all of whom reported one or more concussions during their playing careers, 25% had hearing loss and 50% had tinnitus.[citation needed]

Perinatal conditions

[edit]

These are much more common in premature babies, particularly those under 1500 g at birth. Premature birth can be associated with problems that result in sensorineural hearing loss, such as anoxia or hypoxia (poor oxygen levels), jaundice, intracranial haemorrhages, and meningitis. Fetal alcohol syndrome is reported to cause hearing loss in up to 64% of infants born to alcoholic mothers, from the ototoxic effect on the developing fetus, plus malnutrition during pregnancy from the excess alcohol intake.

Iodine deficiency / Hypothyroidism

[edit]

Iodine deficiency and endemic hypothyroidism are associated with hearing loss.[12] If a pregnant mother has insufficient iodine intake during pregnancy it affects the development of the inner ear in the foetus leading to sensorineural deafness. This occurs in certain areas of the world, such as the Himalayas, where iodine is deficient in the soil and thus the diet. In these areas, there is a high incidence of endemic goitre. This cause of deafness is prevented by adding iodine to salt.

Brain stroke

[edit]

Brain stroke in a region affecting auditory function such as a posterior circulation infarct has been associated with deafness.

Pathophysiology

[edit]

Sensory hearing loss is caused by abnormal structure or function of the hair cells of the organ of Corti in the cochlea.[disputeddiscuss] Neural hearing impairments are consequent upon damage to the eighth cranial nerve (the vestibulocochlear nerve) or the auditory tracts of the brainstem. If higher levels of the auditory tract are affected, this is known as central deafness. Central deafness may present as sensorineural deafness but should be distinguishable from the history and audiological testing.

Cochlear dead regions in sensory hearing loss

[edit]

Hearing impairment may be associated with damage to the hair cells in the cochlea. Sometimes there may be a complete loss of function of inner hair cells (IHCs) over a certain region of the cochlea; this is called a "dead region". The region can be defined in terms of the range of characteristic frequencies (CFs) of the IHCs and/or neurons immediately adjacent to the dead region.

Cochlear hair cells

[edit]
Figure 3: Cross-section of the cochlea.

Outer hair cells (OHCs) contribute to the structure of the Organ of Corti, which is situated between the basilar membrane and the tectorial membrane within the cochlea (See Figure 3). The tunnel of Corti, which runs through the Organ of Corti, divides the OHCs and the inner hair cells (IHCs). OHCs are connected to the reticular lamina and the Deiters' cells. There are roughly twelve thousand OHCs in each human ear, and these are arranged in up to five rows. Each OHC has small tufts of 'hairs', or cilia, on its upper surface known as stereocilia, and these are also arranged into rows which are graded in height. There are approximately 140 stereocilia on each OHC.[13]

The fundamental role of the OHCs and the IHCs is to function as sensory receptors. The main function of the IHCs is to transmit sound information via afferent neurons. They do this by transducing mechanical movements or signals into neural activity. When stimulated, the stereocilia on the IHCs move, causing a flow of electric current to pass through the hair cells. This electric current creates action potentials within the connected afferent neurons.

OHCs are different in that they actually contribute to the active mechanism of the cochlea. They do this by receiving mechanical signals or vibrations along the basilar membrane and transducing them into electrochemical signals. The stereocilia found on OHCs are in contact with the tectorial membrane. Therefore, when the basilar membrane moves due to vibrations, the stereocilia bend. The direction in which they bend dictates the firing rate of the auditory neurons connected to the OHCs.[14]

The bending of the stereocilia towards the basal body of the OHC causes excitation of the hair cell. Thus, an increase in the firing rate of the auditory neurons connected to the hair cell occurs. On the other hand, the bending of the stereocilia away from the basal body of the OHC causes inhibition of the hair cell. Thus, a decrease in the firing rate of the auditory neurons connected to the hair cell occurs. OHCs are unique in that they can contract and expand (electromotility). Therefore, in response to the electrical stimulations provided by the efferent nerve supply, they can alter in length, shape, and stiffness. These changes influence the response of the basilar membrane to sound.[13][14] It is therefore clear that the OHCs play a major role in the active processes of the cochlea.[13] The main function of the active mechanism is to finely tune the basilar membrane and provide it with a high sensitivity to quiet sounds. The active mechanism is dependent on the cochlea being in good physiological condition. However, the cochlea is very susceptible to damage.[14]

Hair cell damage
[edit]

SNHL is most commonly caused by damage to the OHCs and the IHCs.[disputeddiscuss] There are two methods by which they might become damaged. Firstly, the entire hair cell might die. Secondly, the stereocilia might become distorted or destroyed. Damage to the cochlea can occur in several ways, for example, by viral infection, exposure to ototoxic chemicals, and intense noise exposure. Damage to the OHCs results in either a less effective active mechanism or it may not function at all. OHCs contribute to providing a high sensitivity to quiet sounds at a specific range of frequencies (approximately 2–4 kHz). Thus, damage to the OHCs results in the reduction of sensitivity of the basilar membrane to weak sounds. Amplification of these sounds is therefore required in order for the basilar membrane to respond efficiently. IHCs are less susceptible to damage in comparison to the OHCs. However, if they become damaged, this will result in an overall loss of sensitivity.[14]

Neural tuning curves

[edit]

Frequency selectivity

[edit]
Figure 4: Neural tuning curve for normal hearing.

The traveling wave along the basilar membrane peaks at different places along it, depending on whether the sound is low or high frequency. Due to the mass and stiffness of the basilar membrane, low-frequency waves peak in the apex, while high-frequency sounds peak in the basal end of the cochlea.[13] Therefore, each position along the basilar membrane is finely tuned to a particular frequency. These specifically tuned frequencies are referred to as characteristic frequencies (CF).[14]

If a sound entering the ear is displaced from the characteristic frequency, then the strength of response from the basilar membrane will progressively lessen. The fine-tuning of the basilar membrane is created by the input of two separate mechanisms. The first mechanism is a linear passive mechanism, which is dependent on the mechanical structure of the basilar membrane and its surrounding structures. The second mechanism is a non-linear active mechanism, which is primarily dependent on the functioning of the OHCs and also the general physiological condition of the cochlea itself. The base and apex of the basilar membrane differ in stiffness and width, which causes the basilar membrane to respond to varying frequencies differently along its length. The base of the basilar membrane is narrow and stiff, resulting in it responding best to high-frequency sounds. The apex of the basilar membrane is wider and much less stiff in comparison to the base, causing it to respond best to low frequencies.[14]

This selectivity to certain frequencies can be illustrated by neural tuning curves. These demonstrate the frequencies a fiber responds to, by showing threshold levels (dB SPL) of auditory nerve fibers as a function of different frequencies. This demonstrates that auditory nerve fibers respond best, and hence have better thresholds at the fiber's characteristic frequency and frequencies immediately surrounding it. The basilar membrane is said to be 'sharply tuned' due to the sharp V-shaped curve, with its 'tip' centered at the auditory fibers' characteristic frequency. This shape shows how few frequencies a fiber responds to. If it were a broader 'V' shape, it would be responding to more frequencies (See Figure 4).[13]

IHC vs OHC hearing loss

[edit]
Figure 5: Neural tuning curve for OHC loss. Adapted from.[14]
Figure 6: Neural tuning curve for OHC front row loss and IHC loss. Adapted from.[14]

A normal neural tuning curve is characterised by a broadly tuned low frequency 'tail', with a finely tuned middle frequency 'tip'. However, where there is partial or complete damage to the OHCs, but with unharmed IHCs, the resulting tuning curve would show the elimination of sensitivity at the quiet sounds. I.e., where the neural tuning curve would normally be most sensitive (at the 'tip') (See Figure 5).[14]

Where both the OHCs and the IHCs are damaged, the resulting neural tuning curve would show the elimination of sensitivity at the 'tip'. However, due to IHC damage, the whole tuning curve becomes raised, giving a loss of sensitivity across all frequencies (See Figure 6). It is only necessary for the first row of OHCs to be damaged for the elimination of the finely tuned 'tip' to occur. This supports the idea that the incidence of OHC damage and thus a loss of sensitivity to quiet sounds, occurs more than IHC loss.[14]

When the IHCs or part of the basilar membrane are damaged or destroyed, so that they no longer function as transducers, the result is a 'dead region'. Dead regions can be defined in terms of the characteristic frequencies of the IHC, related to the specific place along the basilar membrane where the dead region occurs. Assuming that there has been no shift in the characteristic frequencies relating to certain regions of the basilar membrane due to the damage to OHCs. This often occurs with IHC damage. Dead regions can also be defined by the anatomical place of the non-functioning IHC (such as an "apical dead region"), or by the characteristic frequencies of the IHC adjacent to the dead region.[15]

Dead region audiometry

[edit]

Pure tone audiometry (PTA)

[edit]

Dead regions affect audiometric results, but perhaps not in the way expected. For example, it may be expected that thresholds would not be obtained at the frequencies within the dead region, but would be obtained at frequencies adjacent to the dead region. Therefore, assuming normal hearing exists around the dead region, it would produce an audiogram that has a dramatically steep slope between the frequency where a threshold is obtained, and the frequency where a threshold cannot be obtained due to the dead region.[15]

Figure 7: Response of the basilar membrane to a pure tone.
Figure 8: Response of the basilar membrane to a pure tone, when there is a dead region.

However, it appears that this is not the case. Dead regions cannot be clearly found via PTA audiograms. This may be because the neurons innervating the dead region cannot react to vibration at their characteristic frequency. If the basilar membrane vibration is large enough, neurons tuned to different characteristic frequencies, such as those adjacent to the dead region, will be stimulated due to the spread of excitation. Therefore, a response from the patient at the test frequency will be obtained. This is referred to as "off-place listening", and is also known as 'off-frequency listening'. This will lead to a false threshold being found. Thus, it appears a person has better hearing than they actually do, resulting in a dead region being missed. Therefore, using PTA alone, it is impossible to identify the extent of a dead region (See Figures 7 and 8).[15]

Consequently, how much is an audiometric threshold affected by a tone with its frequency within a dead region? This depends on the location of the dead region. Thresholds at low-frequency dead regions are more inaccurate than those at higher-frequency dead regions. This has been attributed to the fact that excitation due to vibration of the basilar membrane spreads upwards from the apical regions of the basilar membrane, more than excitation spreads downwards from higher frequency basal regions of the cochlea. This pattern of the spread of excitation is similar to the 'upward spread of masking' phenomenon. If the tone is sufficiently loud to produce enough excitation at the normally functioning area of the cochlea, it is above that area's threshold. The tone will be detected, due to off-frequency listening, which results in a misleading threshold.[15]

To help overcome the issue of PTA producing inaccurate thresholds within dead regions, masking of the area beyond the dead region that is being stimulated can be used. This means that the threshold of the responding area is sufficiently raised so that it cannot detect the spread of excitation from the tone. This technique has led to the suggestion that a low-frequency dead region may be related to a loss of 40–50 dB.[16][17] However, as one of the aims of PTA is to determine whether or not there is a dead region, it may be difficult to assess which frequencies to mask without the use of other tests.[15]

Based on research, it has been suggested that a low-frequency dead region may produce a relatively flat loss or a very gradually sloping loss towards the higher frequencies. As the dead region will be less detectable due to the upward spread of excitation. Whereas, there may be a more obvious steeply sloping loss at high frequencies for a high-frequency dead region. Although the slope likely represents the less pronounced downward spread of excitation, rather than accurate thresholds for those frequencies with non-functioning hair cells. Mid-frequency dead regions, with a small range, appear to have less effect on the patient's ability to hear in everyday life, and may produce a notch in the PTA thresholds.[15] Although it is clear that PTA is not the best test to identify a dead region.[18]

Psychoacoustic tuning curves (PTC) and threshold equalizing noise (TEN) tests

[edit]
Figure 9: Psychoacoustical tuning curve.

Although some debate continues regarding the reliability of such tests,[19] it has been suggested [weasel words]that psychoacoustic tuning curves (PTCs) and threshold-equalising noise (TEN) results may be useful in detecting dead regions, rather than PTA. PTCs are similar to neural tuning curves. They illustrate the level of a masker (dB SPL) tone at threshold, as a function of deviation from center frequency (Hz).[13] They are measured by presenting a fixed low intensity pure tone while also presenting a narrow-band masker, with a varying center frequency. The masker level is varied so that the level of masker needed to just mask the test signal is found for the masker at each center frequency. The tip of the PTC is where the masker level needed to just mask the test signal is the lowest. For normal hearing people this is when the masker center frequency is closest to the frequency of the test signal (See Figure 9).[18]

In the case of dead regions, when the test signal lies within the boundaries of a dead region, the tip of the PTC will be shifted to the edge of the dead region, to the area that is still functioning and detecting the spread of excitation from the signal. In the case of a low-frequency dead region, the tip is shifted upwards, indicating a low-frequency dead region starting at the tip of the curve. For a high frequency dead region, the tip is shifted downwards from the signal frequency to the functioning area below the dead region.[18] However, the traditional method of obtaining PTCs is not practical for clinical use, and it has been argued[weasel words] that TENs are not accurate enough.[18][19] A fast method for finding PTCs has been developed, and it may provide the solution. However, more research to validate this method is required before it can be accepted clinically.

Perceptual consequences of a dead region

[edit]

Audiogram configurations are not good indicators of how a dead region will affect a person functionally, mainly due to individual differences.[14] For example, a sloping audiogram is often present with a dead region, due to the spread of excitation. However, the individual may well be affected differently from someone with a corresponding sloped audiogram caused by partial damage to hair cells rather than a dead region. They will perceive sounds differently, yet the audiogram suggests that they have the same degree of loss. Huss and Moore investigated how hearing-impaired patients perceive pure tones, and found that they perceive tones as noisy and distorted, more (on average) than a person without a hearing impairment. However, they also found that the perception of tones as being like noise was not directly related to frequencies within the dead regions and was therefore not an indicator of a dead region. This therefore suggests that audiograms, and their poor representation of dead regions, are inaccurate predictors of a patient's perception of pure tone quality.[20]

Research by Kluk and Moore has shown that dead regions may also affect the patient's perception of frequencies beyond the dead regions. There is an enhancement in the ability to distinguish between tones that differ very slightly in frequency, in regions just beyond the dead regions, compared to tones further away. An explanation for this may be that cortical re-mapping has occurred. Whereby, neurons which would normally be stimulated by the dead region have been reassigned to respond to functioning areas near it. This leads to an over-representation of these areas, resulting in an increased perceptual sensitivity to small frequency differences in tones.[21]

Vestibulocochlear nerve pathology

[edit]
  • congenital deformity of the internal auditory canal,
  • neoplastic and pseudo-neoplastic lesions, with special detailed emphasis on schwannoma of the eighth cranial nerve (acoustic neuroma),
  • non-neoplastic Internal Auditory Canal/CerebelloPontine Angle pathology, including vascular loops,

Diagnosis

[edit]

Case history

[edit]

Before examination, a case history provides guidance about the context of the hearing loss.

  • major concern
  • pregnancy and childbirth information
  • medical history
  • development history
  • family history

Otoscopy

[edit]

Direct examination of the external canal and tympanic membrane (eardrum) with an otoscope, a medical device inserted into the ear canal that uses light to examine the condition of the external ear and tympanic membrane, and middle ear through the semi-translucent membrane.

Differential testing

[edit]

Differential testing is most useful when there is unilateral hearing loss and distinguishes conductive from sensorineural loss. These are conducted with a low-frequency tuning fork, usually 512 Hz, and contrast measures of air and bone conducted sound transmission.

  • Weber test, in which a tuning fork is touched to the midline of the forehead, localizes to the normal ear in people with unilateral sensorineural hearing loss.
  • Rinne test, which tests air conduction vs. bone conduction, is positive, because both bone and air conduction are reduced equally.
  • less common Bing and Schwabach variants of the Rinne test.
  • absolute bone conduction (ABC) test.

Table 1. A table comparing sensorineural to conductive hearing loss

Criteria Sensorineural hearing loss Conductive hearing loss
Anatomical site Inner ear, cranial nerve VIII, or central processing centers Middle ear (ossicular chain), tympanic membrane, or external ear
Weber test Sound localizes to normal ear in unilateral SNHL Sound localizes to the affected ear (ear with conductive loss) in unilateral cases
Rinne test Positive Rinne; air conduction > bone conduction (both air and bone conduction are decreased equally, but the difference between them is unchanged). Negative Rinne; bone conduction > air conduction (bone/air gap)

Other, more complex, tests of auditory function are required to distinguish the different types of hearing loss. Bone conduction thresholds can differentiate sensorineural hearing loss from conductive hearing loss. Other tests, such as oto-acoustic emissions, acoustic stapedial reflexes, speech audiometry, and evoked response audiometry, are needed to distinguish sensory, neural, and auditory processing hearing impairments.

Tympanometry

[edit]

A tympanogram is the result of a test with a tympanometer. It tests the function of the middle ear and the mobility of the eardrum. It can help identify conductive hearing loss due to disease of the middle ear or eardrum from other kinds of hearing loss, including SNHL.

Audiometry

[edit]

An audiogram is the result of a hearing test. The most common type of hearing test is pure tone audiometry (PTA). It charts the thresholds of hearing sensitivity at a selection of standard frequencies between 250 and 8000 Hz. There is also high-frequency pure tone audiometry, which tests frequencies from 8000 to 20,000 Hz. PTA can be used to differentiate between conductive hearing loss, sensorineural hearing loss, and mixed hearing loss. A hearing loss can be described by its degree, i.e., mild, moderate, severe, or profound, or by its shape, i.e., high frequency or sloping, low frequency or rising, notched, U-shaped or 'cookie-bite', peaked or flat.

There are also other kinds of audiometry designed to test hearing acuity rather than sensitivity (speech audiometry), or to test auditory neural pathway transmission (evoked response audiometry).

Magnetic resonance imaging

[edit]

MRI scans can be used to identify gross structural causes of hearing loss. They are used for congenital hearing loss when changes to the shape of the inner ear or nerve of hearing may help diagnose the cause of the hearing loss. They are also useful in cases where a tumour is suspected or to determine the degree of damage in a hearing loss caused by bacterial infection or autoimmune disease. Scanning is of no value in age-related deafness.

Prevention

[edit]

Presbycusis is the leading cause of SNHL and is progressive and nonpreventable, and at this time, heredity-related SNHL can't be countered by either somatic or gene therapy. But other causes of acquired SNHL are largely preventable, especially nosocusis type causes. This would involve avoiding environmental noise and traumatic noise, such as rock concerts and nightclubs with loud music. Use of noise attenuation measures like ear plugs is an alternative, as well as learning about the noise levels one is exposed to. Currently, several accurate sound level measurement apps exist. Reducing exposure time can also help manage risk from loud exposures.

Noise Exposure Limits

Treatment

[edit]

Treatment modalities fall into three categories: pharmacological, surgical, and management. As SNHL is a physiologic degradation and considered permanent, there are currently no approved or recommended treatments.

There have been significant advances in the identification of human deafness genes and elucidation of their cellular mechanisms, as well as their physiological function in mice.[22][23] Nevertheless, pharmacological treatment options are very limited and clinically unproven.[24] Such pharmaceutical treatments as are employed are palliative rather than curative, and addressed to the underlying cause if one can be identified, to avert progressive damage.

Profound or total hearing loss may be amenable to management by cochlear implants, which stimulate cochlear nerve endings directly. A cochlear implant is a surgical implantation of a battery-powered electronic medical device in the inner ear. Unlike hearing aids, which make sounds louder, cochlear implants do the work of the damaged parts of the inner ear (cochlea) to provide sound signals to the brain. These consist of both internal implanted electrodes and magnets, and external components.[25] The quality of sound is different than natural hearing but may enable the recipient to recognize speech and environmental sounds better. Because of risk and expense, such surgery is reserved for cases of severe and disabling hearing impairment

Management of sensorineural hearing loss involves employing strategies to support existing hearing, such as lip-reading, enhanced communication, etc., and amplification using hearing aids. Hearing aids are specifically tuned to the individual's hearing loss to give maximum benefit.

Research

[edit]

Pharmaceuticals

[edit]
  • Antioxidant vitamins – Researchers at the University of Michigan report that a combination of high doses of vitamins A, C, and E, and Magnesium, taken one hour before noise exposure and continued as a once-daily treatment for five days, was very effective at preventing permanent noise-induced hearing loss in animals.[26]
  • Tanakan – a brand name for an international prescription drug extract of Ginkgo biloba. It is classified as a vasodilator. Among its research uses is the treatment of sensorineural deafness and tinnitus presumed to be of vascular origin.
  • Coenzyme Q10 – a substance similar to a vitamin, with antioxidant properties. It is made in the body, but levels fall with age.[Note 3]
  • Ebselen, a synthetic drug molecule that mimics glutathione peroxidase (GPx), a critical enzyme in the inner ear that protects it from damage caused by loud sounds or noise[27]

Stem cell and gene therapy

[edit]

Hair cell regeneration using stem cell and gene therapy is years or decades away from being clinically feasible.[28] However, studies are currently underway on the subject, with the first FDA-approved trial beginning in February 2012.[29]

Sudden sensorineural hearing loss (SSHL)

[edit]

Unlike other types of hearing loss, Sudden Sensorineural Hearing Loss (SSHL or SSNHL) is often treatable if addressed immediately. Commonly known as sudden deafness, it occurs as an unexplained, rapid loss of hearing—usually in one ear—either at once or over several days. Nine out of ten people with SSHL lose hearing in only one ear. It should be considered a medical emergency. Delaying diagnosis and treatment may render treatment less effective or ineffective.

Experts estimate that SSHL strikes one person per 100 every year,[citation needed] typically adults in their 40s and 50s. The actual number of new cases of SSHL each year could be much higher because the condition often goes undiagnosed.

Presentation

[edit]

Many people notice that they have SSHL when they wake up in the morning. Others first notice it when they try to use the deafened ear, such as when they use a phone. Still others notice a loud, alarming "pop" just before their hearing disappears. People with sudden deafness often become dizzy, have ringing in their ears (tinnitus), or both.

Diagnosis

[edit]

SSHL is diagnosed via pure tone audiometry. If the test shows a loss of at least 30 dB in three adjacent frequencies, the hearing loss is formally diagnosed as SSHL (though the treatments may be effective for any level of sudden hearing loss). For example, a hearing loss of 30 dB would make conversational speech sound more like a whisper.

Causes

[edit]

Only 10 to 15 percent of the cases diagnosed as SSHL have an identifiable cause. Most cases are classified as idiopathic, also called sudden idiopathic hearing loss (SIHL) and idiopathic sudden sensorineural hearing loss (ISSHL or ISSNHL)[30][31] The majority of evidence points to some type of inflammation in the inner ear as the most common cause of SSNHL.

  • Infection is believed to be the most common cause of SSNHL, accounting for approximately 13% of cases. Viruses that have been associated with SSNHL include cytomegalovirus, rubella, measles, mumps, human immunodeficiency virus (HIV), herpes simplex virus (HSV), varicella zoster virus (VZV), and West Nile virus.[32] Patients with COVID-19 may also be at increased risk for developing SSNHL.[33]
  • Vascular ischemia of the inner ear or cranial nerve VIII (CN8)
  • Perilymph fistula, usually due to a rupture of the round or oval windows and the leakage of perilymph. The patient will usually also experience vertigo or imbalance. A history of trauma is usually present, and changes to hearing or vertigo occur with alteration in intracranial pressure, such as with straining, lifting, blowing, etc.
  • Autoimmune – can be due to an autoimmune illness such as systemic lupus erythematosus, granulomatosis with polyangiitis

Treatment

[edit]

Immediate treatment from an otolaryngologist (sometimes called an ENT surgeon) is needed. The primary treatment for SSHL is oral Prednisone, and two recent formal studies both found that nearly half the patients fully recovered their hearing. The discussions in the Hodokort 2024 paper are very readable[34], and although it set out to show that higher doses of steroids than normal give better results, it found that the standard German treatment was best (the control), with 45% getting back to normal and at least 84% getting a benefit. The other SeaShel 2024 paper[35] is also very readable, with both systemic steroids and intratympanic injections being used, and again 46% of patients got their hearing audiogram back to normal. The primary treatment was overwhelmingly oral steroids, but over 40% got intratympanic injections at some point (though this did not lead to a greater percentage with full recovery than the Hodokort controls, who all got the same standardized oral treatment). The Seashel paper does not give partial recovery values.

Something patients can do to try to increase the chance of success with Prednisone is to record daily cellphone audiograms (free or with donation at hearingtest.online (setting volume initially at 80%, pleasant and educational), or Apple airpods pro2 or later). If the loss is worse than 60dB then masking is probably also needed, which may be possible by adding noise to the good ear when using hearingtest.online. If the hearing improves, that is excellent. It is “Prednisone responsive”, and it should be possible to discuss the dose with the provider, particularly about adding a long slow taper down from the last 10 mg/day over 1 to 2 weeks, rather than overnight, in order to prevent losing the regained hearing. Natural Cortisol of about 7.5 mg/day has to restart, and although Rheumatologists use a final slow taper, it is not yet standard for hearing treatment. The lack of daily home audiograms is a distinct problem with treatment, with the response to Prednisone not being tracked at all. Facebook groups are a very useful source of information for patients, and there are descriptions of hearing seeming to improve while taking Prednisone, but then relapsing by the time of the single formal audiogram that may be recorded days or weeks later.

A 2022 literature review indicates that systemic oral steroids are the best choice initially[36]. It says: “For primary therapy, intratympanic corticosteroids may have little or no effect compared with systemic corticosteroids”. A 2025 paper includes hyperbaric oxygen therapy (HBOT)[37], which is also sometimes used. Steroid treatment within seven days, a lower initial severity of hearing loss, the absence of vertigo, younger patient age, and a history of cardiovascular disease(?) are all associated with complete hearing recovery.[35]. [An older reference here was about hearing loss completely recovering in around 35–39% of patients on its own, usually within one to two weeks from onset, based on older information before Prednisone treatment became standard. It says in the Hodokort paper introduction that not providing treatment is not an option now, and perhaps this should just be left for the Drs to discuss. [38]].

  • vitamins and antioxidants
  • vasodilators
  • betahistine (Betaserc), an anti-vertigo drug
  • hyperbaric oxygen[39]
  • rheologic agents that reduce blood viscosity (such as hydroxyethyl starch, dextran and pentoxifylline)[40]
  • anti-inflammatory agents, primarily oral corticosteroids (such as prednisone and dexamethasone)[41]
  • Intratympanic administration – Gel formulations are under investigation to provide more consistent drug delivery to the inner ear.[42] Local drug delivery can be accomplished through intratympanic administration, a minimally invasive procedure where the ear drum is anesthetized and a drug is administered into the middle ear. From the middle ear, a drug can diffuse across the round window membrane into the inner ear.[42] Intratympanic administration of steroids may be effective for sudden sensorineural hearing loss for some patients, but high-quality clinical data have not been generated.[43] Intratympanic administration of an anti-apoptotic peptide (JNK inhibitor) is currently being evaluated in late-stage clinical development.[44]

Epidemiology

[edit]

General hearing loss affects close to 10% of the global population.[45] In the United States alone, it is expected that 13.5 million Americans have sensorineural hearing loss. Of those with sensorineural hearing loss, approximately 50% are congenitally related. The other 50% are due to maternal or fetal infections, post-natal infections, viral infections due to rubella or cytomegalovirus, ototoxic drugs,[46] exposure to loud sounds, severe head trauma, and premature births[47]

Of the genetically related sensorineural hearing loss cases, 75% are autosomal recessive, 15-20% autosomal dominant, and 1-3% sex-linked. While the specific gene and protein is still unknown, mutations in the connexin 26 gene near the DFNB1 locus of chromosome 13[48] are thought to account for most of the autosomal recessive genetic-related sensorineural hearing loss[47]

At least 8.5 per 1000 children younger than age 18 have sensorineural hearing loss. General hearing loss is proportionally related to age. At least 314 per 1000 people older than age 65 have hearing loss. Several risk factors for sensorineural hearing loss have been studied over the past decade. Osteoporosis, stapedectomy surgery, pneumococcal vaccinations, mobile phone users, and hyperbilirubinemia at birth are among some of the known risk factors.

See also

[edit]

Notes

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Sensorineural hearing loss (SNHL) is a type of hearing impairment resulting from damage to the structures, particularly the cochlea's cells, the , or the pathways that process signals. This condition accounts for the majority of permanent cases and is typically irreversible because human cells do not regenerate, though emerging gene therapies as of 2025 show promise in preclinical and early clinical trials. Unlike , which involves outer or blockages, SNHL disrupts the sensory or neural transmission of , often leading to difficulties in understanding speech, especially in noisy environments. SNHL can arise from a variety of causes, broadly categorized as congenital or acquired. Congenital forms may be syndromic (associated with genetic syndromes) or nonsyndromic, while acquired causes include age-related degeneration (presbycusis), exposure to excessive noise (noise-induced hearing loss), ototoxic medications (such as certain antibiotics like gentamicin), infections (e.g., meningitis), head trauma, autoimmune disorders, and tumors like vestibular schwannoma. Noise-induced SNHL occurs when intense sounds damage cochlear hair cells by causing excessive bending of their stereocilia, leading to cell death; sounds above 85 decibels (dBA), such as those from concerts or machinery, pose significant risk. Risk factors encompass aging (prevalence doubles every decade after age 20, affecting nearly all individuals over 80), hereditary predisposition, occupational or recreational noise exposure, and certain systemic conditions. As of 2025, over 1.5 billion people worldwide live with some degree of hearing loss, the majority attributable to SNHL. Common symptoms of SNHL include gradual or sudden reduction in hearing acuity, often starting with high-frequency sounds, muffling of speech, tinnitus (perceived sounds such as ringing, roaring, whooshing, or buzzing in the ears), aural fullness, and balance issues like disequilibrium or vertigo in some cases. For instance, typically presents as difficulty discerning consonants and understanding words in , while sudden SNHL—defined as a loss of 30 dB or more over three contiguous frequencies within 72 hours—may affect one and is considered a . Epidemiologically, SNHL is widespread; in the United States, sudden SNHL incidence ranges from 5 to 27 cases per 100,000 people annually, and noise contributes to about 16% of adult globally. Diagnosis involves audiometric testing, such as to measure hearing thresholds and to assess function, supplemented by tests (e.g., and Weber) and imaging like MRI for underlying pathologies. Treatment varies by and severity but focuses on symptom and rehabilitation, as the loss is often permanent. Acute cases, particularly sudden SNHL, may respond to oral corticosteroids (e.g., at 1 mg/kg/day) within the first two weeks, with 32-65% spontaneous recovery possible. For chronic SNHL, options include hearing aids to amplify or cochlear implants for profound losses exceeding 70-80 dB; prevention strategies emphasize avoiding loud noises through ear protection and regular hearing screenings. Early intervention improves , reducing risks of and cognitive decline associated with untreated .

Overview

Definition and types

Sensorineural hearing loss (SNHL) is a permanent type of hearing impairment caused by damage to the structures, particularly the 's hair cells, or the auditory nerve, which prevents the proper transmission of sound vibrations from the cochlea to the . This damage disrupts the conversion of mechanical sound waves into electrical signals that the interprets as sound, leading to difficulties in hearing faint or quiet sounds and often affecting speech understanding. SNHL is distinct from , which results from obstructions or damage in the outer or that block sound waves from reaching the , such as earwax buildup or middle ear infections. In contrast, SNHL involves pathology beyond the , with no air-bone gap observed on audiometric testing. Mixed hearing loss occurs when both conductive and sensorineural components are present simultaneously. Classifications of SNHL include distinctions by and : unilateral (affecting one ) or bilateral (affecting both ), and symmetric (similar severity in both ) or asymmetric (varying severity between ). By onset, it can be congenital (present from birth) or acquired (developing after birth). Regarding progression, SNHL may be stable (non-worsening) or progressive (gradually deteriorating over time). Severity is determined by pure-tone average hearing thresholds across key frequencies (500, 1000, 2000, and 4000 Hz): mild (26–40 dB), moderate (41–60 dB), severe (61–80 dB), or profound (≥81 dB). The concept of what is now termed SNHL, often referred to as nerve deafness in early descriptions, emerged in 19th-century amid debates on congenital and acquired auditory impairments. Modern systems, including severity grading, evolved from audiometric standards set by the in the early 1990s.

Epidemiology

Sensorineural hearing loss (SNHL) represents a significant burden, affecting approximately 430 million people worldwide with disabling hearing impairment as of 2025, the majority of which is sensorineural in nature. This prevalence equates to over 5% of the world's population requiring rehabilitation, with projections estimating that by 2050, nearly 2.5 billion individuals will experience some degree of , including over 700 million with disabling forms primarily due to aging populations and persistent risk factors. Age-related SNHL, known as presbycusis, is the predominant form in older adults, accounting for a substantial portion of cases and affecting about one-third of individuals aged 65 to 74 and nearly half of those over 75. The incidence of disabling , largely sensorineural, increases markedly with age, from around 10% in adults aged 55 to 64 to 22% in those 65 to 74 and 55% in individuals 75 and older. Demographic disparities exacerbate the burden, with males experiencing higher rates due to greater occupational and recreational noise exposure. Regional variations show elevated in low- and middle-income countries, where untreated infections contribute significantly and nearly 80% of people with disabling live, compared to higher-income settings. Congenital SNHL affects approximately 1 to 3 per 1,000 live births, underscoring its impact from early life. Recent trends indicate post-2020 increases in SNHL incidence linked to infection and associated , particularly sudden sensorineural hearing loss among young adults, with risks rising notably from 2020 to 2022. The World Health Organization's 2025 updates highlight noise-induced SNHL as a growing concern in urban youth, with over 1 billion young adults at risk from unsafe listening practices involving personal audio devices.

Signs and symptoms

Auditory manifestations

Sensorineural hearing loss (SNHL) primarily manifests as difficulty understanding speech, especially in noisy environments, where individuals struggle with discriminating speech signals from background noise due to impaired auditory processing. This core symptom arises from damage to the or auditory nerve, leading to reduced clarity in perceiving nuanced sound patterns essential for communication. In daily life, affected individuals may frequently ask others to repeat themselves, withdraw from social gatherings, or rely on visual cues like lip-reading to compensate for the deficit. The auditory effects often vary by the frequency range of the loss. High-frequency SNHL, the most common form, impairs perception of such as /s/, /f/, /sh/, and /th/, resulting in muffled or indistinct speech that sounds blurred or slurred. In contrast, low-frequency SNHL affects sounds like /a/, /e/, and /o/, which carry much of the intensity and rhythm in speech, leading to challenges in distinguishing words with similar patterns and altering the prosody of . These frequency-specific deficits highlight how SNHL disrupts the components critical for intelligible . The severity of SNHL influences the extent of auditory impairment, progressing from mild to profound levels. In mild cases (26–40 dB hearing level), subtle mishearing of words or soft speech occurs, particularly in quiet settings, allowing functional hearing in ideal conditions. Moderate to severe losses (41–90 dB) intensify speech comprehension difficulties, making conversations laborious even without noise. Profound SNHL (>91 dB) results in near-complete , where only very loud sounds are detectable, severely limiting auditory input. Associated auditory issues include , an abnormal rapid growth in perceived for sounds above the hearing threshold, which can make moderate noises uncomfortably intense despite overall hearing reduction. , characterized by intolerance to ordinary environmental sounds, affects 40-86% of individuals with comorbid in cases of auditory pathologies including SNHL, exacerbating discomfort in everyday auditory exposure. , a frequent , presents as phantom noises like ringing, further complicating auditory experiences.

Non-auditory effects

Sensorineural hearing loss (SNHL) often affects the due to the anatomical proximity of the and vestibular organs within the , leading to symptoms such as , imbalance, and vertigo in approximately 28-57% of cases involving sudden onset SNHL. These vestibular disturbances can manifest as acute vertigo attacks, contributing to falls and reduced mobility, particularly in older adults where balance impairment exacerbates daily functional limitations. Beyond balance issues, SNHL is associated with cognitive decline, including an elevated risk of that is nearly twofold higher in affected individuals compared to those without , as evidenced by meta-analyses of longitudinal studies. Untreated SNHL contributes to this risk through mechanisms like and increased from auditory processing deficits, while communication barriers often lead to and heightened depressive symptoms, with affected adults reporting more negative emotional responses and situational limitations. In children, SNHL significantly impacts developmental milestones, causing delays in that persist even with mild to severe degrees of loss, resulting in depressed expressive and receptive skills relative to hearing peers. These language delays frequently translate to academic underperformance, including challenges in and classroom participation, underscoring the need for early intervention to mitigate long-term educational disparities. Overall, SNHL diminishes , as measured by tools like the Hearing Handicap Inventory for Adults (HHIA), where individuals commonly report reduced social participation scores indicative of mild to severe handicaps in emotional and situational domains. For instance, higher HHIA totals correlate with greater perceived barriers to , highlighting the broader toll of the condition.

Causes

Genetic factors

Genetic causes account for approximately 50-60% of cases of sensorineural hearing loss (SNHL) in childhood, with autosomal recessive inheritance being the most prevalent pattern among prelingual forms. Congenital SNHL affects about 1-2 per 1,000 newborns, as identified through universal newborn hearing screening programs. These genetic etiologies can be classified as nonsyndromic, where occurs in isolation, or syndromic, involving additional clinical features. Among nonsyndromic forms, mutations in the GJB2 gene, encoding connexin 26, are the most common, responsible for 20–50% of congenital cases depending on population and ethnicity, and more than half of autosomal recessive nonsyndromic SNHL overall. The DFNB1 locus, primarily involving GJB2 variants, exemplifies autosomal recessive inheritance (DFNB), which predominates in genetic childhood SNHL. Autosomal dominant patterns (DFNA) are less frequent, typically causing postlingual progressive loss, while X-linked (DFNX) and mitochondrial forms are rarer. Mutations in the OTOF gene, encoding otoferlin, are linked to auditory neuropathy spectrum disorder, a subset of SNHL characterized by disrupted synaptic transmission in the . Mitochondrial inheritance contributes to SNHL through mutations like A1555G in the MT-RNR1 gene, which predisposes individuals to nonsyndromic hearing loss and heightened sensitivity to . In syndromic SNHL, combines congenital to severe SNHL with leading to vision loss, inherited mostly autosomally recessive. features SNHL alongside pigmentation abnormalities, such as heterochromia iridis or white forelock, and follows autosomal dominant transmission in most cases.

Acquired factors

Acquired sensorineural hearing loss (SNHL) encompasses a range of non-genetic etiologies that develop after birth, often due to environmental exposures, medical interventions, or physiological insults that damage the or auditory nerve. These factors are modifiable in many cases through preventive measures, contrasting with congenital or hereditary forms. Common contributors include noise exposure, ototoxic medications, infections, aging, trauma, autoimmune processes, neoplasms, and perinatal complications, each leading to irreversible loss or neural degeneration. Noise exposure is a leading environmental cause of acquired SNHL, particularly from occupational or recreational sources exceeding safe thresholds. Prolonged exposure to sounds above 85 decibels (dB) or impulse noises surpassing 140 dB can trigger , resulting in permanent high-frequency hearing deficits. Globally, occupational noise accounts for approximately 16% of disabling among adults, affecting millions through cumulative damage to cochlear hair cells. Ototoxic drugs represent a significant iatrogenic , damaging structures via mechanisms such as or direct . antibiotics, including gentamicin, carry a 20-50% of ototoxicity, often manifesting as bilateral, high-frequency SNHL in vulnerable patients like those with renal impairment. , used in , induces in up to 60-90% of pediatric cases and 23-50% of adults, depending on cumulative dose and co-administration with other agents. , such as , contribute to transient or permanent SNHL in 6-7% of users, particularly when combined with other ototoxins or in high doses. Infections can precipitate acute or progressive SNHL by direct viral invasion of the cochlea or secondary inflammation. Bacterial or viral meningitis leads to SNHL in 10-30% of cases, with higher rates in children due to labyrinthitis ossificans or neural involvement. Mumps virus causes unilateral SNHL in approximately 0.005–0.5% of infections, typically sudden and sensorineural in nature, though often mild to moderate. Studies from 2020-2025 indicate that COVID-19 is associated with auditory sequelae, including SNHL, in 5-20% of symptomatic patients, potentially linked to viral neurotropism or vascular effects. Aging, or , drives acquired SNHL through cumulative and vascular changes in the , affecting over 25% of adults aged 65 and older. Head trauma, especially temporal bone fractures from severe impacts, disrupts the auditory nerve or in up to 30-50% of cases, leading to immediate or delayed SNHL. Autoimmune inner ear disease (AIED) involves immune-mediated inflammation, causing rapid, progressive, often fluctuating bilateral SNHL that may respond to immunosuppressive therapy if diagnosed early. Neoplasms, such as (acoustic neuroma), can cause progressive unilateral SNHL by compressing the auditory nerve. Perinatal factors heighten SNHL risk in neonates, particularly among preterm or low-birth-weight infants. Prematurity independently increases susceptibility, with prevalence rising as gestational age decreases below 32 weeks due to immature cochlear development and intensive care exposures. Hyperbilirubinemia, or neonatal jaundice, correlates with SNHL through bilirubin-induced neurotoxicity, especially when levels exceed 20 mg/dL or require exchange transfusion. Low birth weight (<1500 g) elevates risk via associated complications like hypoxia or mechanical ventilation, observed in up to 2-5% of very low-birth-weight infants.

Pathophysiology

Inner ear mechanisms

Sensorineural hearing loss (SNHL) primarily arises from damage to the sensory structures within the cochlea, particularly the hair cells that transduce mechanical sound vibrations into neural signals. The cochlea houses two types of hair cells: inner hair cells (IHCs) and outer hair cells (OHCs). IHCs function as primary sensory transducers, converting basilar membrane motion into neurotransmitter release at ribbon synapses that convey auditory information to spiral ganglion neurons of the auditory nerve. In contrast, OHCs actively amplify weak sounds through electromotility, a process driven by conformational changes in the motor protein prestin in response to receptor potentials, which enhances cochlear sensitivity and sharpens frequency tuning. Loss of OHCs diminishes this amplification, leading to reduced dynamic range and elevated thresholds, while IHC loss disrupts signal transmission, often resulting in more severe auditory deficits. A key feature of cochlear pathology in SNHL is the development of dead regions, which are contiguous zones of the organ of Corti where IHCs or their associated neurons are sufficiently dysfunctional that they cannot effectively contribute to sound encoding for specific frequencies. These regions typically occur at frequencies where hearing thresholds exceed 70-80 dB HL, as off-frequency hair cells with lower thresholds may respond to tones but with poor fidelity, leading to broadened auditory filters and diminished frequency selectivity. Consequently, sounds in dead regions are misrepresented by adjacent functional areas, contributing to distorted pitch perception and reduced speech intelligibility in noise. The underlying mechanisms of hair cell damage in SNHL involve multiple cellular stressors that culminate in cell death or dysfunction. Noise exposure and ototoxins, such as aminoglycoside antibiotics and cisplatin, trigger oxidative stress through reactive oxygen species (ROS) accumulation, activating pathways like JNK and p38 MAPK that promote apoptosis in hair cells. This oxidative damage often targets stereocilia, the mechanosensitive projections on hair cell apical surfaces, causing tip-link breakage and impaired mechano-transduction—the process by which ion channels open in response to stereocilia deflection to depolarize the cell. Stereocilia injury reduces the hair cell's ability to detect basilar membrane vibrations, further exacerbating signal loss. The basilar membrane's tonotopic organization maps sound frequencies along its length, with high frequencies at the base and low frequencies at the apex, enabling frequency-specific activation of hair cells in healthy cochleae. Neural tuning curves, which reflect the frequency selectivity of auditory nerve fibers innervating these hair cells, are sharply peaked in normal ears, allowing precise discrimination of close frequencies. In SNHL, hair cell loss—particularly of OHCs—broadens these tuning curves by reducing active mechanical sharpening, resulting in poorer frequency resolution and increased spread of excitation across the cochlea. This broadening correlates with the degree of hearing loss and contributes to central auditory processing challenges downstream.

Neural components

Sensorineural hearing loss (SNHL) can involve disruptions beyond the cochlea, extending to the auditory nerve and central auditory pathways, where synaptic, neural, and cortical changes impair sound transmission and processing. A key neural component is cochlear synaptopathy, often termed "hidden hearing loss," which arises from damage to the ribbon synapses connecting inner hair cells to auditory nerve fibers, without affecting pure-tone thresholds. This condition is exemplified by noise-induced cochlear neuropathy, where even moderate noise exposure leads to selective loss of these synapses, resulting in difficulties understanding speech in noisy environments despite normal audiograms. The prevalence of cochlear synaptopathy in humans remains uncertain and is an active area of research, primarily inferred from animal models and limited human studies showing associations with noise exposure and difficulties in speech perception in noise. Diagnosis of cochlear synaptopathy in humans is challenging due to the lack of a standardized clinical test as of 2025, with research focusing on advanced auditory brainstem response measures and perceptual tests. Auditory nerve pathology contributes to retrocochlear forms of SNHL, where lesions disrupt nerve fiber integrity and signal conduction. Acoustic neuroma, a benign tumor on the vestibulocochlear nerve, compresses auditory nerve fibers, leading to progressive unilateral hearing loss, tinnitus, and balance issues due to impaired neural transmission. In auditory neuropathy spectrum disorder (ANSD), demyelination or axonal degeneration of the auditory nerve prevents synchronized neural firing, resulting in poor speech perception despite preserved cochlear function; this disorder accounts for approximately 5-15% of pediatric SNHL cases. Central auditory effects in SNHL involve reorganization of the auditory cortex and brainstem pathways, altering sound processing. Hearing loss triggers maladaptive plasticity in the auditory cortex, where reduced input leads to expanded representation of unaffected frequencies and heightened neural gain, often manifesting as tinnitus through aberrant hyperactivity. This reorganization also impairs temporal processing, diminishing the ability to resolve rapid acoustic changes essential for speech discrimination. The vestibulocochlear nerve (cranial nerve VIII) is particularly vulnerable to compression or ischemia, exacerbating SNHL through direct neural compromise. Tumors or vascular anomalies can compress the nerve, while ischemic events, such as infarction in the anterior inferior cerebellar artery territory, cause acute hearing loss by disrupting nerve perfusion and conduction. These pathologies highlight the nerve's role in integrating auditory and vestibular signals, with ischemia often presenting as sudden, profound unilateral SNHL accompanied by vertigo.

Diagnosis

History and examination

The evaluation of sensorineural hearing loss (SNHL) begins with a detailed case history to identify potential etiologies and guide differential diagnosis. Key elements include the onset of hearing loss, which may be sudden (defined as occurring over 72 hours or less) or gradual and progressive, and its laterality (unilateral or bilateral). Family history is essential to assess for genetic predispositions, such as hereditary syndromes, while inquiries into occupational or recreational noise exposure, head trauma, or barotrauma help identify acquired causes. A review of medications, particularly ototoxic agents like aminoglycosides, loop diuretics, or chemotherapy drugs, is critical, as is noting associated symptoms such as tinnitus, vertigo, disequilibrium, aural fullness, or focal neurologic deficits. Otoscopy, a visual inspection of the external auditory canal and tympanic membrane using an otoscope, is performed to rule out external or middle ear pathologies that could mimic or contribute to hearing loss. In pure SNHL, the otoscopic findings are typically normal, with no evidence of cerumen impaction, infection, perforation, or neoplasms. This step helps differentiate SNHL from conductive hearing loss, though adjunctive tests like tympanometry may be used briefly to exclude middle ear effusion if indicated. The physical examination extends to bedside tuning fork tests using a 512-Hz fork to further characterize the hearing loss. In the Rinne test, air conduction is compared to bone conduction; a positive Rinne (air conduction better than bone conduction) supports SNHL, while the Weber test involves placing the vibrating fork on the midline forehead, with sound lateralizing to the better-hearing ear in unilateral SNHL. A comprehensive cranial nerve assessment, particularly of nerves I through XII, is also conducted as part of a head and neck examination to identify any associated neurologic involvement, though findings are often normal in isolated SNHL. Red flags in the history and examination, such as sudden unilateral hearing loss or accompanying vertigo and neurologic symptoms, necessitate urgent referral to otolaryngology for timely intervention, potentially including corticosteroids within two weeks of onset to improve recovery chances. Significant asymmetry (e.g., ≥15 dB at 3000 Hz) requires prompt referral for evaluation and imaging.

Audiometric tests

Audiometric tests are essential for confirming the presence of sensorineural hearing loss (SNHL) and quantifying its severity and configuration, distinguishing it from conductive losses through objective and behavioral measures. These assessments evaluate the integrity of the cochlea and auditory nerve, providing thresholds and patterns that guide diagnosis and management. Pure-tone audiometry (PTA) is the cornerstone of audiometric evaluation, measuring hearing thresholds for pure tones presented via air conduction (headphones) and bone conduction (vibrator on the mastoid). In SNHL, thresholds overlap between air and bone conduction with an air-bone gap typically less than 10 dB hearing level (dB HL), confirming the sensorineural origin without middle ear involvement. A classic audiometric pattern in many cases of SNHL, such as age-related presbycusis or noise-induced loss, is a bilateral, gently to steeply sloping high-frequency configuration, where thresholds worsen progressively above 2 kHz, reflecting damage to basal cochlear structures. This test quantifies the degree of loss—mild (26-40 dB HL), moderate (41-55 dB HL), severe (71-90 dB HL), or profound (>90 dB HL)—based on the average of thresholds at 500, 1000, 2000, and 4000 Hz. Speech audiometry complements PTA by assessing functional hearing for speech, measuring speech detection threshold (SDT), speech recognition threshold (SRT), and word recognition score (WRS) using phonetically balanced word lists presented at comfortable levels. In SNHL, particularly cochlear forms, WRS is disproportionately reduced compared to pure-tone thresholds due to impaired frequency resolution and temporal processing; for instance, severe SNHL often yields WRS below 20%, indicating over 80% loss in word recognition even at suprathreshold levels. This discrepancy helps differentiate SNHL from purely conductive losses, where WRS typically aligns better with amplified thresholds. Objective electrophysiological tests like otoacoustic emissions (OAEs) and (ABR) provide non-behavioral confirmation of SNHL components. Transient evoked OAEs (TEOAEs) and distortion product OAEs (DPOAEs), generated by outer s, are typically absent or significantly reduced in cochlear SNHL, indicating outer hair cell dysfunction even if behavioral thresholds are only mildly elevated. ABR, which records neural synchrony along the auditory pathway in response to clicks or tones, evaluates neural integrity; in pure cochlear SNHL, wave latencies and amplitudes may show elevated thresholds but preserved morphology, whereas retrocochlear involvement prolongs I-V interpeak latency. These tests are particularly valuable in infants, uncooperative patients, or when behavioral responses are unreliable. To identify cochlear dead regions—areas of inner loss that contribute to poor in SNHL—the threshold equalizing noise (TEN) masks pure tones with noise calibrated to equalize audibility across frequencies. A dead region is indicated if the masked tone threshold exceeds the unmasked threshold by more than 10 dB or rises above the noise level by 10 dB, highlighting regions where off-frequency listening cannot compensate, often in sloping high-frequency losses. This informs hearing aid fitting by suggesting avoidance of amplification in dead regions to prevent distortion.

Imaging and advanced diagnostics

Imaging plays a crucial role in evaluating sensorineural hearing loss (SNHL) when structural abnormalities or retrocochlear are suspected, particularly in cases of unilateral, asymmetric, or sudden-onset hearing loss. These indications warrant to identify potential etiologies such as or trauma, as symmetric bilateral SNHL is less likely to yield positive findings on routine scans. Magnetic resonance imaging (MRI) serves as the gold standard for detecting retrocochlear lesions like acoustic neuroma (), which can present with unilateral SNHL. -enhanced T1-weighted sequences provide high sensitivity, approximately 95-100%, for identifying these tumors by enhancing the solid components of the lesion within the internal auditory canal or . Non-contrast high-resolution T2-weighted imaging can also detect such lesions with 84-100% sensitivity in screening contexts, though remains preferred for definitive evaluation. Abnormal (ABR) findings may further prompt MRI to rule out retrocochlear involvement. Computed tomography (CT) of the is particularly useful for assessing bony structures in SNHL associated with trauma or processes. High-resolution CT excels at delineating fractures of the otic capsule, which occur in approximately 5% of fractures and often lead to profound SNHL, as well as labyrinthine that may complicate cochlear implantation. It provides detailed visualization of cochlear anatomy and the canal, aiding in preoperative planning for cases like post-traumatic ossifying labyrinthitis. Advanced diagnostic techniques extend beyond structural imaging to electrophysiological and metabolic assessments. (ECoG), an objective test measuring electrical potentials, is valuable for detecting endolymphatic hydrops, a condition linked to SNHL in disorders like , with transtympanic tone-burst ECoG showing high sensitivity for . In research settings, (PET) evaluates metabolic activity in auditory pathways, revealing glucose hypometabolism in the and among patients with asymmetric or noise-induced SNHL, which correlates with the degree of hearing impairment.

Prevention

Lifestyle measures

Lifestyle measures play a crucial role in mitigating the risk of sensorineural hearing loss (SNHL) by addressing modifiable daily habits that influence health. These strategies focus on reducing exposure to damaging factors such as , , vascular impairments, and infections, supported by evidence from epidemiological and clinical studies. Adopting these practices can help preserve auditory function over time, particularly for individuals at higher risk due to age or environmental exposures. A primary lifestyle intervention involves noise avoidance to prevent noise-induced SNHL, which damages cochlear hair cells through mechanical and metabolic stress. Limiting exposure to sounds at or above 85 dBA is recommended, as prolonged or repeated exposure at this level can lead to permanent threshold shifts. For recreational settings like concerts, where sound levels often exceed 100 dBA, using earplugs provides effective protection; a demonstrated that earplugs significantly reduce temporary threshold shifts post-exposure, thereby lowering the cumulative risk of permanent hearing damage. Custom or high-fidelity earplugs that attenuate noise while preserving sound quality are particularly beneficial for frequent attendees. Dietary habits and overall health management also contribute to SNHL prevention by counteracting , a key pathophysiological mechanism in cochlear degeneration. Consuming antioxidant-rich foods high in vitamins A, C, and E—such as leafy greens, citrus fruits, nuts, and seeds—helps neutralize free radicals that damage structures; meta-analyses indicate that higher dietary intake of these antioxidants is inversely associated with risk. Additionally, controlling chronic conditions like diabetes and hypertension through balanced diet, exercise, and medication adherence reduces vascular complications that impair cochlear blood flow and exacerbate SNHL. Effective glycemic control in , for instance, lowers the odds of auditory impairment by mitigating neuropathy and microangiopathy. Smoking cessation is another essential measure, as tobacco use promotes vascular damage and that accelerate SNHL progression. Current smokers exhibit higher rates of high-frequency hearing thresholds compared to non-smokers, with the risk linked to nicotine-induced and in the . Quitting smoking diminishes this elevated risk over time, with longitudinal studies showing improved auditory outcomes and reduced hearing impairment severity among former smokers, particularly within years of cessation. Support programs combining counseling and enhance success rates for this modifiable behavior. Proper ear hygiene practices further safeguard against SNHL by preventing complications from trauma or infection. Individuals should avoid inserting cotton swabs into the ear canal, as this can push cerumen deeper, cause epithelial trauma, or perforate the tympanic membrane, potentially leading to infections and secondary hearing damage. Instead, ears self-clean through jaw movement, and excess wax can be managed by wiping the outer ear or seeking professional removal. Prompt treatment of ear infections, such as acute otitis media, is vital; untreated cases can spread to the inner ear in rare instances, causing labyrinthitis and sensorineural damage via inflammation or bacterial toxins. Early antibiotic therapy or drainage, guided by medical evaluation, minimizes these risks.

Occupational safeguards

Occupational safeguards against sensorineural hearing loss primarily target noise-induced damage through regulatory standards, workplace engineering, protective equipment, and monitoring in high-risk sectors. These measures aim to limit exposure to hazardous noise levels, which can cause irreversible cochlear hair cell damage and auditory nerve impairment. In the United States, the (OSHA) enforces a of 90 decibels A-scale (dBA) as an 8-hour time-weighted average, requiring employers to implement feasible controls to prevent exceeding this threshold. When noise reaches the action level of 85 dBA over 8 hours, OSHA mandates a hearing conservation program that includes noise monitoring, employee training, and provision of hearing protectors at no cost. In the , Directive 2003/10/EC sets lower and upper exposure action values at 80 dB and 85 dB, respectively, prompting employers to conduct risk assessments, measure exposure, and apply preventive measures; the exposure limit value is 87 dB, with mandatory health surveillance for affected workers. Engineering controls prioritize reducing noise at the source, such as through acoustic barriers, vibration-dampening materials on machinery, and substitution with quieter equipment, which can lower workplace levels by 10-20 dB or more depending on . Integral to these efforts are hearing conservation programs, which require annual audiometric testing—baseline within 6 months of exposure and subsequent tests compared to detect standard threshold shifts of 10 dB or greater at 2,000, 3,000, or 4,000 Hz—to enable early intervention and program adjustments. Personal protective equipment serves as essential backup when engineering solutions are insufficient, with custom-molded earplugs and over-ear typically attenuating by 15-30 dB when fitted correctly, though effectiveness depends on consistent use and proper seal. Employers must select devices based on levels and ensure on fit and maintenance to achieve rated ratings (NRR). These safeguards are critical in high-risk industries like , where about 14% of workers report hearing difficulties attributable to occupational from tools and machinery. Manufacturing sees similar vulnerabilities, with roughly 20% of noise-exposed workers experiencing hearing impairment due to prolonged exposure in assembly and processing environments. In the , blast exposure from weapons and explosions poses acute risks, contributing to hearing loss in approximately 15% of active-duty personnel.

Management

Non-surgical options

Non-surgical management of sensorineural hearing loss (SNHL) primarily involves amplification devices, assistive technologies, rehabilitative therapies, and for acute cases, aiming to improve auditory and communication without invasive procedures. These approaches are recommended as first-line treatments for mild to moderate SNHL, where residual hearing can be effectively utilized. Hearing aids are the cornerstone of amplification for SNHL, consisting of digital devices that amplify specific frequencies tailored to the individual's audiogram to compensate for high-frequency losses commonly seen in this condition. Modern digital hearing aids process sound through programmable microchips, reducing background noise and enhancing speech clarity. Many individuals with mild to moderate SNHL experience significant benefit in speech understanding and quality of life from hearing aids, though outcomes depend on factors like degree of loss and user adaptation. Over-the-counter (OTC) hearing aids, approved by the U.S. Food and Drug Administration in 2022 for adults with self-perceived mild to moderate hearing loss, offer a self-fitting, affordable option without requiring a medical evaluation or professional adjustment. Common styles include behind-the-ear (BTE) aids, which sit comfortably behind the ear and connect via a tube to a custom earpiece, suitable for a wide range of losses; and in-the-canal (ITC) aids, which fit partially in the ear canal for a more discreet appearance and are ideal for mild to moderate cases. BTE models are versatile for children and those with dexterity issues, while ITC aids minimize occlusion effects. Assistive listening devices complement hearing aids in challenging environments, such as noisy group settings, by directly transmitting sound to the user. systems, for example, use a worn by the speaker to send signals to a receiver connected to the , improving by up to 15-20 dB and enhancing speech comprehension in reverberant or distant scenarios. Captioning devices, including real-time text displays for lectures, television, or phone calls, provide visual support for auditory input, particularly beneficial in educational or social gatherings where acoustic challenges persist despite amplification. These tools are often portable and can be used independently or integrated with hearing aids via telecoil technology. Aural rehabilitation focuses on training to optimize communication skills and psychological adjustment for those with SNHL. Speechreading, also known as lipreading, involves visual cues from facial movements to supplement auditory signals, with structured training improving recognition of consonants and words in noisy conditions. Auditory training programs, delivered through apps or clinician-guided sessions, enhance the brain's processing of amplified sounds, fostering better discrimination of phonemes and environmental noises; examples include software like (Listening and Communication Enhancement) that progressively increases difficulty. Counseling components address emotional aspects, such as stigma or frustration, promoting acceptance and strategies for in conversations. These interventions, often combined with amplification, yield sustained improvements in social participation when initiated early. For acute inflammatory or sudden SNHL, with corticosteroids is a standard non-surgical intervention to reduce cochlear swelling and promote recovery. Oral , typically dosed at 1 mg/kg body weight daily (up to 60 mg) for 7-14 days followed by a taper, is administered promptly to maximize efficacy. Clinical studies indicate partial to complete hearing recovery in approximately 50-60% of cases when treatment begins within two weeks of onset, with better outcomes in milder losses. This approach is particularly effective for idiopathic sudden SNHL presumed to involve viral or autoimmune mechanisms. For severe or profound SNHL unresponsive to aids, evaluation for candidacy may be considered, but non-surgical options remain prioritized initially.

Surgical interventions

Surgical interventions for sensorineural hearing loss (SNHL) are typically reserved for cases of severe to profound bilateral loss where non-surgical options, such as hearing aids, provide insufficient benefit. These procedures aim to bypass damaged structures or enhance sound transmission, particularly when the auditory nerve remains functional. Common indications include profound SNHL exceeding 70 dB hearing threshold with poor speech discrimination scores below 50% in the better ear. Cochlear implants represent the primary surgical treatment for profound SNHL, involving the implantation of an electrode array directly into the to electrically stimulate the auditory nerve, thereby restoring some auditory perception. Candidates are generally adults or children with bilateral severe-to-profound SNHL who derive limited benefit from conventional amplification, often after audiometric confirmation of thresholds greater than 70 dB and scores under 50%. Post-implantation, approximately 80-90% of recipients demonstrate significant improvements in , particularly in quiet environments, enabling better communication and . Patients unresponsive to hearing aids are frequently referred for this intervention when rehabilitation goals cannot be met otherwise. Bone-anchored hearing aids (BAHA) are surgically implanted devices suitable for mixed hearing loss, where a conductive component overlays the sensorineural deficit, such as in chronic otitis media or congenital malformations. The procedure involves anchoring a titanium fixture to the skull behind the ear, which transmits vibrations through bone conduction to the functioning cochlea, bypassing outer and middle ear issues. Indications include air-bone gaps greater than 10 dB with underlying SNHL, typically in patients over age 5 who cannot tolerate traditional hearing aids due to skin sensitivities or poor acoustics. Outcomes often yield improved sound localization and speech understanding in noise for those with mixed losses. For cases where the auditory nerve is absent or nonfunctional, such as in type 2, auditory brainstem implants (ABI) provide an alternative by directly stimulating the in the . These are indicated for patients ineligible for cochlear implants due to bilateral auditory nerve loss, often following tumor resection, with implantation typically performed in individuals aged 12 or older. ABIs restore basic sound awareness and limited speech detection, though outcomes vary and generally offer less robust perception than cochlear implants. Stapedotomy, while primarily addressing in , is rarely applied when sensorineural involvement complicates the condition, aiming to improve overall auditory transmission by replacing the fixed footplate. All surgical interventions carry risks, including infection rates of 2-5% that may necessitate device revision or removal, and damage occurring in less than 1% of cases, potentially leading to temporary or permanent . Meticulous surgical technique and preoperative imaging minimize these complications, with most resolving without long-term sequelae.

Prognosis

Factors influencing outcomes

Several factors influence the progression of sensorineural hearing loss (SNHL) and the success of interventions, enabling more personalized prognostic assessments. Early intervention plays a critical role, particularly in cases of sudden SNHL, where treatment initiation within 2 weeks of onset significantly enhances hearing recovery compared to later administration, as delayed treatment leads to diminished auditory amplitude. In broader SNHL contexts, prompt amplification or implantation, especially in children, yields superior auditory performance and , with early cochlear implantation demonstrating statistically significant long-term benefits in and acquisition. Additionally, bilateral symmetric often responds more favorably to hearing aids than asymmetric or unilateral forms, with bilateral fitting improving in noise and overall sound quality for the majority of users. Conversely, prolonged duration of untreated SNHL adversely affects outcomes by altering neural plasticity; hearing losses exceeding several years promote maladaptive cortical reorganization, reducing the efficacy of subsequent rehabilitation efforts. Damage to inner ear hair cells or the auditory nerve in chronic cases lasting over a decade is usually irreversible, as these structures do not regenerate, and acute treatments such as steroids or hyperbaric oxygen therapy are ineffective for long-term hearing restoration in these scenarios. Comorbidities such as diabetes mellitus accelerate SNHL progression through mechanisms like and neuropathy, with affected individuals showing higher rates of bilateral sensorineural impairment and faster hearing threshold deterioration compared to non-diabetic populations. Severity at baseline also modulates treatment efficacy, notably in cochlear implantation, where preservation of residual low-frequency hearing post-surgery correlates with enhanced speech understanding in noisy environments and more natural sound perception, as electro-acoustic stimulation leverages remaining acoustic input for better overall outcomes. Outcomes differ markedly between pediatric and adult populations due to variations in neural plasticity. Children with early-onset SNHL who receive cochlear implants within the first few years of life often achieve near-normal and receptive skills, supported by heightened developmental plasticity that facilitates auditory integration. In contrast, adults with longstanding SNHL experience more variable improvements in following implantation, with untreated loss contributing to potential cognitive declines over time, though rehabilitation still yields benefits in communication and . Variability in sudden-onset cases underscores the importance of these factors, as detailed in specific etiological assessments.

Long-term impacts

Sensorineural hearing loss (SNHL) often leads to profound social consequences, including increased isolation as individuals withdraw from social settings such as group conversations or events due to communication difficulties. This isolation is compounded by reduced opportunities, with systematic reviews indicating a higher likelihood of or among affected adults. Furthermore, untreated SNHL is associated with lower odds of compared to those with normal hearing, contributing to diminished income and financial strain. Relationship strain is also common, as persistent misunderstandings and frustration from impaired communication can escalate arguments and erode emotional bonds between partners or family members. On the health front, long-term SNHL elevates the risk of cognitive decline, with mild cases doubling the likelihood of , moderate cases tripling it, and severe cases increasing it fivefold. A 2023 randomized (ACHIEVE study) found that hearing aids slowed the rate of cognitive decline by 48% over three years in older adults with and elevated risk. Balance issues arise from the vestibular involvement in the , with even mild untreated tripling the risk of falls. Economically, unaddressed SNHL imposes a substantial global burden, estimated at over $980 billion annually in , encompassing lost productivity, caregiving costs, and quality-of-life reductions. In the workforce, this manifests as decreased participation and output, particularly in communication-intensive roles, amplifying individual and societal financial pressures. Effective management through hearing aids or cochlear implants can substantially mitigate these impacts, with devices often restoring 70-90% of function in suitable candidates, thereby reducing isolation, supporting , and lowering associated risks.

Research

Gene and stem cell therapies

represents a promising avenue for treating hereditary forms of sensorineural hearing loss (SNHL), particularly those caused by mutations in genes essential for auditory function, such as otoferlin (OTOF). (AAV) vectors are commonly employed to deliver functional copies of these genes directly to cells, aiming to restore protein expression and synaptic transmission in cochlear hair cells. Preclinical studies in animal models of OTOF deficiency have shown that AAV-mediated OTOF delivery leads to otoferlin expression in inner hair cells, resulting in partial or full restoration of auditory brainstem responses and improved hearing thresholds. A key example is SENS-501 (OTOF-GT), an investigational AAV-based therapy developed by Sensorion for children with OTOF-related congenital deafness. In non-human primate and rodent models, SENS-501 has demonstrated safe transduction of cochlear cells with sustained otoferlin expression, correlating with hearing recovery without significant off-target effects. The Phase 1/2 AUDIOGENE advanced with completion of enrollment for the second cohort of infants aged 6-31 months by August 2025; initial data from the first cohort, announced in July 2025, confirmed good tolerability, no serious adverse events related to the therapy, and early efficacy signals including improved auditory responses in treated ears. For acquired SNHL, often resulting from ototoxic damage or exposure, gene therapy strategies emphasize regeneration of lost s through targeted overexpression of transcription factors. ATOH1, a key regulator of differentiation, has been delivered via AAV vectors in preclinical models of cochlear injury, inducing supporting cells to transdifferentiate into functional s. 2025 studies report enhanced auditory evoked potentials and counts in - or drug-exposed mice following ATOH1 overexpression, highlighting its role in promoting regeneration without tumorigenic risks observed in earlier approaches. Stem cell-based interventions complement by providing cellular replacement for damaged cochlear structures. (iPSC)-derived otic progenitors, which mimic early precursors, have been transplanted into the to repair loss in preclinical models. Earlier work at the showed that human iPSC-derived progenitors survive transplantation, migrate to sensory regions, differentiate into -like cells, and form synaptic connections in deafened cochleae, leading to improved hearing recovery. Recent efforts from , through spin-out Rinri Therapeutics, focus on iPSC-derived progenitors for auditory regeneration; in 2025, Rinri announced plans for Phase 1 trials of Rincell-1 to treat severe due to damage. Ongoing preclinical work has optimized protocols for progenitor expansion and delivery, paving the way for clinical translation in regenerative therapies for both hereditary and acquired SNHL. Despite these advancements, several challenges hinder the widespread application of gene and therapies for SNHL. Immune responses to AAV vectors can elicit in the sensitive , potentially reducing transduction efficiency and causing transient hearing fluctuations, as observed in some studies. Delivery remains a critical barrier, requiring minimally invasive techniques like round window injection to avoid trauma to cochlear fluids and structures. Ethical concerns also arise, particularly regarding editing to correct heritable mutations, necessitating rigorous oversight to balance therapeutic benefits with risks of off-target genetic changes.

Pharmacological and regenerative approaches

Pharmacological interventions for sensorineural hearing loss (SNHL) focus on neuroprotective agents that mitigate damage to cochlear structures, particularly hair cells and synapses. such as (BDNF) and (NT-3) have demonstrated protective effects against synaptic loss in preclinical models of and noise exposure. For instance, early transtympanic administration of recombinant human BDNF (rhBDNF) provides multifaceted , including preservation of synaptic ribbons and reduction of in cisplatin-induced hearing loss models. Similarly, NT-3 infused via hydrogels extends release and supports spiral ganglion neuron survival, enhancing auditory synapse integrity. The NOTOXIS Phase 2a trial of SENS-401 for preventing cisplatin-induced completed patient enrollment in March 2025, with topline results anticipated in late 2025. Antioxidant therapies target reactive oxygen species implicated in noise-induced and sudden SNHL. Ebselen, formulated as SPI-1005, reduces temporary and permanent threshold shifts in noise-induced hearing loss by inhibiting inflammatory pathways and protecting cochlear hair cells, as shown in phase 2 randomized trials. Phase 3 results from December 2024 confirmed SPI-1005's efficacy in improving auditory function in Meniere's disease, a condition often involving sensorineural components. Exploratory applications to sudden SNHL are supported by data from Meniere's and noise-induced models. By 2025, clinical data continued to highlight SPI-1005's role in mitigating acute noise-induced loss, supporting its potential as an oral preventive agent. Regenerative approaches leverage advanced delivery systems and scaffolds to promote hair cell and neuronal repair. Functionalized nanoparticles enable targeted cochlear delivery of therapeutics, overcoming the blood-labyrinth barrier for precise localization to auditory epithelium. In 2025 preclinical studies, these nanoparticles improved hair cell survival rates by up to 40% in ototoxic models through enhanced uptake and reduced off-target effects. Such systems also facilitate gene delivery for regeneration, though detailed mechanisms are addressed in gene therapy contexts. Biomaterial-based strategies, particularly hydrogels, mimic the inner ear's to sustain drug release and foster cellular integration. Bioactive hydrogels loaded with or antioxidants enhance drug efficacy by providing controlled over weeks, reducing inflammation and supporting differentiation in models. 2025 research demonstrated that dynamic click hydrogels improve adhesion and survival within the cochlear microenvironment, achieving greater than 50% integration rates in preclinical regeneration assays. These scaffolds not only amplify pharmacological effects but also promote endogenous repair by simulating native tissue stiffness and bioactivity. Integration of artificial intelligence (AI) in these approaches aids in developing predictive models for therapy personalization. Machine learning algorithms analyze genetic and audiometric data to forecast treatment responses in sudden SNHL, enabling tailored pharmacological regimens with accuracies exceeding 85% in 2025 validation studies. Such models prioritize candidates for neurotrophin or antioxidant interventions based on ototoxicity risk profiles, accelerating clinical decision-making.

Sudden sensorineural hearing loss

Presentation and initial assessment

Sudden sensorineural hearing loss (SSNHL) is defined as a hearing impairment of at least 30 decibels (dB) across three consecutive frequencies occurring within a 72-hour period. This condition is unilateral in approximately 90% of cases, distinguishing it from bilateral progressive forms of sensorineural hearing loss. Patients typically present with an abrupt onset of unilateral hearing loss, often described as a sudden "drop" in auditory perception or muffled hearing that can range from mild to profound severity. Accompanying symptoms are common and include tinnitus in about 70% of individuals, which may manifest as ringing, buzzing, roaring, whooshing, or seashell-like sounds in the affected ear, and vertigo or dizziness in 30-50% of cases, potentially indicating involvement of the vestibular system. While SSNHL shares some features with general sensorineural hearing loss symptoms, such as muffled hearing, its acute and rapid progression prompts immediate medical attention. Patients experiencing sudden muffled hearing accompanied by tinnitus (such as roaring, whooshing, or seashell-like sounds) should seek prompt medical evaluation, as this presentation may indicate SSNHL, a medical emergency in which early evaluation and treatment (such as corticosteroids) can improve recovery chances. Initial assessment begins with an urgent clinical history to identify potential precipitants, including recent viral infections, head trauma, or exposure to ototoxic medications. Physical examination includes otoscopy, which typically reveals a normal tympanic membrane without signs of effusion or external canal abnormalities, helping to differentiate SSNHL from . Bedside is performed promptly to confirm the sensorineural nature of the loss through air and testing, often followed by referral for full audiometric evaluation if not immediately available. The differential diagnosis for SSNHL includes conditions such as , characterized by herpes zoster infection with facial palsy and vesicular rash, and perilymph fistula, which may follow or and present with fluctuating alongside vertigo. Early recognition of these mimics is crucial, as they may require distinct management approaches beyond standard SSNHL protocols.

Etiology and risk factors

Sudden sensorineural hearing loss (SSNHL) is idiopathic in 85-90% of cases, with no identifiable cause despite extensive evaluation. Among the hypothesized etiologies for non-idiopathic cases, viral infections play a prominent role, particularly (HSV) and (), which may trigger inner ear inflammation or direct cochlear damage. Vascular mechanisms, such as occlusion leading to ischemia in the , are also frequently proposed, supported by histopathological evidence of reduced blood flow in affected structures. Several risk factors predispose individuals to SSNHL, including cardiovascular conditions like and , which are associated with an approximately 1.5- to 2-fold increased risk through promotion of vascular compromise. Autoimmune diseases, such as systemic lupus erythematosus and , elevate susceptibility by inducing immune-mediated cochlear injury. Recent upper respiratory infections further heighten risk, potentially via viral spread to the or secondary inflammatory responses, with epidemiological data showing a temporal association in up to 20-30% of cases. Less common etiologies include head trauma, which can result in perilymphatic fistula—a tear in the membranes separating the inner and , allowing leakage and sudden auditory disruption. represents a rare cause, typically involving metastatic invasion of the or acoustic nerve compression, as documented in isolated case reports. Some studies have reported associations between COVID-19 infection and SSNHL, though the incidence in COVID-19 patients is low (less than 1%), possibly due to viral neurotropism or hypercoagulability.

Diagnostic approach

The diagnosis of sudden sensorineural hearing loss (SSNHL) begins with a detailed and to confirm the acute onset and sensorineural nature of the hearing deficit, followed by urgent audiometric evaluation to quantify the loss and differentiate it from conductive causes. (PTA) is the cornerstone, measuring thresholds across frequencies to identify a sensorineural loss of at least 30 dB over three or more contiguous frequencies that develops within 72 hours or less. Speech audiometry, including speech recognition threshold and word scores, is performed concurrently to assess functional hearing impairment, often revealing reduced discrimination disproportionate to pure-tone thresholds in SSNHL. Common audiometric configurations include flat (uniform loss across frequencies) or down-sloping (greater high-frequency involvement) patterns, which help characterize the loss but do not alter initial management urgency. Laboratory testing is not routinely recommended for all patients with SSNHL, as it rarely identifies a specific and does not influence standard treatment; however, targeted tests are appropriate based on clinical suspicion to exclude mimics or risk factors. For suspected autoimmune processes, such as Cogan syndrome or , a (CBC) to detect or and (ESR) to assess inflammation may be obtained. In cases with cardiovascular risk factors or suspicion of vascular compromise, a can evaluate for as a potential contributor to cochlear ischemia. These tests should be guided by the patient's history, such as recent infections or comorbidities, rather than performed indiscriminately. Imaging plays a critical role in ruling out retrocochlear pathology or central causes that require immediate intervention. Clinicians should offer gadolinium-enhanced (MRI) of the internal auditory canal and , particularly if asymmetric loss, vertigo, or neurological signs suggest tumor, , or ; this facilitates exclusion of treatable conditions like or acute infarction. If MRI is unavailable or contraindicated, (ABR) testing serves as an alternative to screen for retrocochlear involvement. In the presence of head trauma or suspicion of temporal bone fracture, non-contrast computed (CT) of the temporal bones is preferred for its superior bone detail. Advanced diagnostic tests are reserved for atypical presentations or to investigate specific etiologies when standard evaluations are inconclusive. (ECochG), which measures the summating potential to ratio via transtympanic , can detect endolymphatic hydrops in patients with low-frequency predominant loss suggestive of early Meniere disease, aiding in targeted management. Blood tests for viral , such as IgM/IgG titers for , , or varicella-zoster, may be considered if prodromal symptoms like fever or indicate an infectious trigger, though yields are low in idiopathic cases. These modalities enhance diagnostic precision but are not first-line due to limited availability and specificity.

Therapeutic strategies

The primary therapeutic approach for sudden sensorineural hearing loss (SSNHL) involves systemic corticosteroids, typically administered as oral prednisone at a dose of 1 mg/kg/day (often around 60 mg daily) for 7-14 days followed by a taper over 10-14 days. This regimen is recommended by clinical practice guidelines as a first-line option for idiopathic cases, with evidence showing recovery rates of 50-65% when initiated within 2 weeks of symptom onset, particularly for mild to moderate hearing losses. Intratympanic corticosteroid injections, such as dexamethasone delivered directly to the middle ear, serve as an alternative primary treatment or adjunct to systemic therapy, offering targeted delivery with reduced systemic side effects and comparable efficacy in early intervention. Hyperbaric oxygen therapy (HBOT) is employed as an adjunctive treatment for idiopathic SSNHL, involving sessions in a pressurized chamber (typically 2.0-2.5 atmospheres absolute for 60-90 minutes daily over 10-20 sessions) to enhance oxygenation of the . Updated 2025 guidelines endorse HBOT within 14 days of onset in combination with steroids, demonstrating an additional 20-30% improvement in hearing recovery rates compared to steroids alone, especially in moderate to severe cases. Antiviral agents like acyclovir (typically 800 mg five times daily for 7-10 days) are considered only if a viral etiology such as herpes zoster oticus is clinically suspected, though systematic reviews indicate limited overall evidence for their routine use in idiopathic SSNHL, with no significant benefit over steroids alone in most cases. For refractory SSNHL—defined as incomplete response after 2 weeks of initial —salvage strategies focus on intratympanic dexamethasone injections (e.g., 4 mg/mL, 0.4-0.5 mL per session, 4-6 times over 1-2 weeks) or combination regimens including HBOT, which may be offered as salvage therapy within the 1-month window after onset for idiopathic cases, though potential benefits are likely reduced compared to earlier treatment with evidence of diminishing returns after 1-2 weeks; some patients experience improvement when combined with steroids. Recent 2025 studies report partial hearing recovery in 25-40% of non-responders with these approaches, with intratympanic delivery showing superior outcomes in salvage settings due to higher local concentrations and lower systemic exposure. In cases of permanent profound deficit following failed interventions, cochlear implantation may be considered for auditory rehabilitation.

Outcomes and epidemiology

The incidence of sudden sensorineural hearing loss (SSNHL) ranges from 5 to 20 cases per 100,000 persons annually worldwide. Some studies suggest seasonal variations in incidence, with higher rates observed in winter potentially linked to increased viral infections. occurs in 32% to 65% of SSNHL cases without intervention. Complete recovery is more likely in mild cases (hearing loss <50 dB), affecting approximately 50% of such patients, whereas profound hearing loss or delayed presentation beyond two weeks correlates with poor and lower recovery rates. In refractory SSNHL cases unresponsive to initial treatments, a 2025 meta-analysis reported complete recovery in only 9.6% of patients. Key prognostic factors include the presence of vertigo at onset, which approximately halves the odds of meaningful recovery ( 2.22), and younger age (<60 years), which is associated with improved outcomes. Long-term, approximately 30% of unresolved SSNHL cases progress to chronic sensorineural hearing loss, while persists in about 40% of affected individuals.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.